NCT04713072 is a Phase 2 clinical trial of ABY-035 in Psoriatic Arthritis, sponsored by ACELYRIN Inc..

Who is sponsoring NCT04713072?

NCT04713072 is sponsored by ACELYRIN Inc..

What drugs are being tested in NCT04713072?

Interventions in NCT04713072: ABY-035, Placebo.

What condition does NCT04713072 study?

NCT04713072 studies Psoriatic Arthritis.

Is NCT04713072 still recruiting?

NCT04713072 is currently completed. Last updated 9 February 2024.

Last reviewed 2024-02-09 · How we verify

NCT04713072

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Completed Phase 2 Last updated 9 February 2024

What this trial tests

Phase 2 trial testing ABY-035 in Psoriatic Arthritis in 129 participants. Completed in 27 January 2022.

Timeline

4 August 2020

Primary endpoint
1 October 2021

27 January 2022

Quick facts

Lead sponsor	ACELYRIN Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	129
Start date	4 August 2020
Primary completion	1 October 2021
Estimated completion	27 January 2022
Sites	32 locations across Belgium, Austria, Germany, Hungary, Poland, Spain, Czechia

Drugs / interventions tested

ABY-035 — full drug profile →
Placebo

Conditions studied

Psoriatic Arthritis — all drugs for Psoriatic Arthritis →

Sponsor

ACELYRIN Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035 in adult patients with PsA.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.
Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, et al · · 2023 · cited 37× · PMID 37184136 · DOI 10.1080/19420862.2023.2209920
IL-23 orchestrating immune cell activation in arthritis.
Najm A, McInnes IB. · · 2021 · cited 18× · PMID 34668017 · DOI 10.1093/rheumatology/keab266
The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.
Katsouli O, Lainis V, Goules AV, Vlachoyiannopoulos PG. · · 2026 · PMID 41648061 · DOI 10.31138/mjr.020925.aar
Exploring the Cutting Edge: A Recap of EULAR & ACR 2023 Highlights for Spondyloarthritis, including Psoriatic Arthritis.
Gerolymatou N, Voulgari PV. · · 2024 · PMID 39974593 · DOI 10.31138/mjr.040524.aeh

Verify or expand the search:

Other trials of ABY-035

Trials testing the same drug.

NCT04795141 — ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis · Phase 2 · terminated
NCT03591887 — A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis · Phase 2 · completed

Other recruiting trials for Psoriatic Arthritis

Currently open trials in the same condition.

NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting

Other ACELYRIN Inc. trials

Trials by the same sponsor.

NCT05905783 — Hidradenitis Suppurativa Study of Izokibep · Phase 3 · terminated
NCT05683496 — Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) · Phase 1, PHASE2 · completed
NCT05623345 — Psoriatic Arthritis Study of Izokibep · Phase 2, PHASE3 · terminated
NCT05384249 — Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis · Phase 2 · terminated
NCT05355805 — Hidradenitis Suppurativa Phase 2b Study of Izokibep · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04713072 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ACELYRIN Inc.
Last refreshed: 9 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04713072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing